High sensitivity C-reactive protein in cardiovascular disease and type 2 diabetes: evidence for a clinical role?

Sign In to gain access to subscriptions and/or personal tools.

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted
	Citation Map

Services

	Email this article to a friend
	Similar articles in this journal
	Alert me to new issues of the journal
	Add to Saved Citations
	Download to citation manager
	Request Permissions
	Request Reprints
	Add to My Marked Citations

Citing Articles

	Citing Articles via Google Scholar
	Citing Articles via Scopus

Google Scholar

	Articles by Sattar, N.
	Search for Related Content

Social Bookmarking

	What's this?

Naveed Sattar

University of Glasgow, Department of Clinical Biochemistry, Glasgow Royal Infirmary, Glasgow, G31 2ER, Scotland, UK, nsattar{at}clinmed.gla.ac.uk

References

Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Danesh J., Whincup P., Walker M. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.[Abstract/Free Full Text]

Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.[Abstract/Free Full Text]

Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.[Free Full Text]

Verma S., Szmitko PE, Ridker PM C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2005;2:29-36; quiz 58.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Liao JK Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005;96:24F-33F.[Web of Science][Medline] [Order article via Infotrieve]

Ridker PM, Cannon CP, Morrow D. et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.[Abstract/Free Full Text]

Danesh J., Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.[Abstract/Free Full Text]

Greenland P., O'Malley PG When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch Intern Med 2005;165:2454-6.[Free Full Text]

Wilson PW, Nam BH, Pencina M., D'Agostino RB, Sr., Benjamin EJ, O'Donnell CJ C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005;165:2473-8.[Abstract/Free Full Text]

Lowe GD Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005;3:1618-27.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Sattar N., McConnachie A., O'Reilly D. et al. Inverse association between birth weight and C-reactive protein concentrations in the MIDSPAN Family Study. Arterioscler Thromb Vasc Biol 2004;24:583-7.[Abstract/Free Full Text]

Miller M., Zhan M., Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 2005;165:2063-8.[Abstract/Free Full Text]

Verma S., Wang CH, Li SH et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-19.[Abstract/Free Full Text]

Taylor KE, Giddings JC, van den Berg CW C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 2005;25:1225-30.[Abstract/Free Full Text]

Hirschfield GM, Gallimore JR, Kahan MC et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2005;102:8309-14.[Abstract/Free Full Text]

Baigent C., Keech A., Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Casas JP, Shah T., Cooper J. et al. C-reactive Protein is a Marker but not a Cause of Myocardial Infarction in Caucasian Men: Evidence against causality using Mendelian Randomisation. Int J Epidemiol. In press.

Koenig W., Sund M., Frohlich M., Lowel H., Hutchinson WL, Pepys MB Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987. Am J Epidemiol 2003;158:357-64.[Abstract/Free Full Text]

Campbell B., Badrick T., Flatman R., Kanowski D. Limited clinical utility of high-sensitivity plasma C-reactive protein assays. Ann Clin Biochem 2002;39:85-8.[Abstract/Free Full Text]

Freeman DJ, Norrie J., Caslake MJ et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596-600.[Abstract/Free Full Text]

Sattar N., Gaw A., Scherbakova O. et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-19.[Abstract/Free Full Text]

Timpson NJ, Lawlor DA, Harbord RM et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 2005;366:1954-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Haffner SM, Greenberg AS, Weston WM, Chen H., Williams K., Freed MI Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.[Abstract/Free Full Text]

Haffner S., Temprosa M., Crandall J. et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005;54:1566-72.[Abstract/Free Full Text]

Cai D., Yuan M., Frantz DF et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med